ImmunityBio initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado initiated coverage of ImmunityBio (IBRX) with a Buy rating and $8 price target ImmunityBio is a clinical-stage biotechnology company advancing next-generation immunotherapies, with its flagship product, Anktiva, serving as the foundation of its pipeline, the analyst tells investors in a research note. The firm believes Anktiva is positioned to expand the unresponsive non-muscle invasive bladder cancer market.